Arrowhead Research Corporation (ARWR) Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01
8/30/2012 10:04:02 AM
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored. An analysis of final study data is being prepared.
comments powered by